MiniMed announces closing of Initial Public Offering

Rhea-AI Summary

MiniMed (Nasdaq: MMED) closed its initial public offering, selling 28,000,000 shares at $20.00 per share and began Nasdaq trading on March 6, 2026. Net proceeds to MiniMed were approximately $538 million after underwriting discounts and expenses.

As of closing, Medtronic owns ~90.03% of MiniMed common stock. MiniMed intends to use part of the proceeds for general corporate purposes and used the remainder to repay intercompany debt owed to Medtronic.

Positive

• Net proceeds of approximately $538 million raised
• IPO of 28,000,000 shares priced at $20.00
• Listing on Nasdaq Global Select Market (started March 6, 2026)
• Proceeds used to repay intercompany debt to Medtronic

Negative

• Medtronic retains approximately 90.03% ownership, limiting public float
• Public float concentration may constrain immediate liquidity for MMED shares

Key Figures

IPO share count: 28,000,000 shares IPO price: $20.00 per share Net proceeds: $538 million +5 more

8 metrics

IPO share count 28,000,000 shares Initial public offering size

IPO price $20.00 per share IPO pricing to the public

Net proceeds $538 million Net proceeds to MiniMed after underwriting and expenses

Medtronic ownership 90.03% Medtronic post-IPO ownership of MiniMed common stock

Trading start date March 6, 2026 First trading day on Nasdaq Global Select Market

Current price $18.00 Price prior to this news vs $20.00 IPO price

52-week high $20.4823 Upper end of recent trading range

52-week low $18.25 Lower end of recent trading range

Market Reality Check

Price: $18.33 Vol: Volume 1,944,976 is below...

low vol

$18.33 Last Close

Volume Volume 1,944,976 is below the 20-day average of 8,820,910, suggesting lighter post-IPO trading activity. low

Technical Shares at $18.00 are trading below the 200-day MA of $18.49 and under the $20.00 IPO price.

Market Pulse Summary

This announcement confirms the closing of MiniMed’s IPO of 28,000,000 shares at $20.00 per share, ge...

Analysis

This announcement confirms the closing of MiniMed’s IPO of 28,000,000 shares at $20.00 per share, generating net proceeds of about $538 million. A portion is earmarked for general corporate purposes, with the remainder used to repay intercompany debt to Medtronic, which retains 90.03% ownership. With trading having started on March 6, 2026, investors may watch how shares behave around the IPO price and within the initial $18.25–$20.4823 range.

Key Terms

initial public offering, ipo, intercompany debt, prospectus, +4 more

8 terms

initial public offering financial

"announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

ipo financial

"initial public offering (IPO) of 28,000,000 shares of its common stock"

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

intercompany debt financial

"The remainder have been used to repay intercompany debt owed to Medtronic."

Intercompany debt is money one legal entity in a corporate group owes to another within the same overall company — essentially an IOU between sister companies or between a parent and its subsidiary. Investors care because these internal loans affect reported cash, liabilities and profit across the group, can hide where real risk or liquidity sits, and may be restructured or written off in ways that change shareholder value or signal financial stress.

prospectus regulatory

"The offering was made only by means of a prospectus. Copies of the prospectus relating to the IPO"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

registration statement regulatory

"A registration statement on Form S-1 relating to these securities has been filed"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form s-1 regulatory

"A registration statement on Form S-1 relating to these securities has been filed"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

u.s. securities and exchange commission regulatory

"declared effective by, the U.S. Securities and Exchange Commission (SEC)."

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

nasdaq global select market financial

"The shares began trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

AI-generated analysis. Not financial advice.

NORTHRIDGE, Calif., March 9, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares began trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026 under the symbol "MMED."

As of the closing of the IPO, Medtronic plc (Medtronic) owns approximately 90.03% of MiniMed common stock. Medtronic has previously stated that its preferred path to complete the separation is a split-off.

After deducting underwriting discounts and commissions and estimated offering expenses payable by MiniMed, the net proceeds to MiniMed were approximately $538 million. MiniMed intends to use a portion of the net proceeds for general corporate purposes. The remainder have been used to repay intercompany debt owed to Medtronic.

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley acted as the active bookrunners for the offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and Piper Sandler also acted as joint book running managers and BTIG and William Blair & Company, L.L.C. acted as co-managers. The offering was made only by means of a prospectus. Copies of the prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com.

A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO. Important factors that could cause actual results to differ materially from management's expectations include, without limitation: capital market risks and the impact of general economic or industry conditions. There can be no guarantees that MiniMed will achieve the anticipated benefits of the IPO. The ability of MiniMed or Medtronic to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed or Medtronic, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside the control of MiniMed or Medtronic. For additional information about the factors that affect Medtronic's and MiniMed's businesses, please see their respective filings with the SEC. Each of Medtronic and MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

MiniMed Contacts
Janet Cho
Public Relations
+1-818-403-7028

Ryan Weispfenning
Investor Relations
+1-763-505-4626 

View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-announces-closing-of-initial-public-offering-302708611.html

SOURCE MiniMed

FAQ

When did MiniMed (MMED) begin trading on Nasdaq and under what symbol?

MiniMed began trading on the Nasdaq Global Select Market on March 6, 2026 under the symbol MMED. According to the company, the listing followed the closing of its IPO of 28,000,000 shares priced at $20.00 per share.

How much did MiniMed (MMED) raise in net proceeds from the IPO?

MiniMed received approximately $538 million in net proceeds after underwriting discounts and estimated offering expenses. According to the company, some proceeds will fund general corporate purposes and the remainder repaid intercompany debt to Medtronic.

What percentage of MiniMed (MMED) does Medtronic own after the IPO?

Medtronic owns approximately 90.03% of MiniMed common stock following the IPO closing. According to the company, Medtronic has indicated a preferred split-off path to complete the separation in the future.

What did MiniMed (MMED) say it will use the IPO proceeds for?

MiniMed intends to use a portion of the net proceeds for general corporate purposes and used the remainder to repay intercompany debt owed to Medtronic. According to the company, repayment reduced amounts owed to its former parent.

Who acted as lead bookrunners on MiniMed's (MMED) IPO?

Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley were the active bookrunners for the offering. According to the company, several other banks acted as joint book running managers and co-managers on the transaction.